Centhaquine

Phase 3Small molecule

PPharmazz, Inc.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hypovolemic ShockRecruiting

Hypovolemic ShockPhase 3

Recruiting

Timeline

Expected Milestones

Q1 2027

ApprovedRecruiting

Hypovolemic Shock

NCT05956418

Q4 2027

Phase 2Not yet recruiting

Acute Respiratory Distress Syndrome (ARDS)

NCT05241067

Q4 2028

Phase 3Not yet recruiting

Hypovolemic Shock

NCT05251181

Clinical

Trials by Indication[1]

Hypovolemic Shock4 trials

PMZ-2010 (Centhaquine) as a Resuscitative Agent for Hypovolemic Shock

Completed·PPharmazz, Inc.·Phase 2·NCT04056065·50 enrolled

Efficacy of PMZ-2010 (Centhaquine) a Resuscitative Agent for Hypovolemic Shock

Completed·PPharmazz, Inc.·Phase 3·NCT04045327·105 enrolled

A Prospective, Multi-centric, Open-labeled, Phase-IV Study to Assess Safety and Efficacy of LYFAQUIN™ (Centhaquine Citrate) as a Resuscitative Agent for Hypovolemic Shock to be Used as an Adjuvant to Standard Treatment of Shock

Recruiting·PPharmazz, Inc.·Approved·NCT05956418·400 enrolled

Show 1 more trial

A Multi-Centric, Randomized, Double-Blind, Placebo-controlled, Phase-III Study to Assess Safety and Efficacy of Centhaquine as a Resuscitative Agent to be Used as an Adjuvant to Standard Treatment of Hypovolemic Shock

Not yet recruiting·PPharmazz, Inc.·Phase 3·NCT05251181·430 enrolled

Acute Respiratory Distress Syndrome (ARDS)1 trial

A Multicentric, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Centhaquine as an Adjuvant to the Standard of Care in Patients With Moderate to Severe Acute Respiratory Distress Syndrome (ARDS)

Not yet recruiting·PPharmazz, Inc.·Phase 2·NCT05241067·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Centhaquine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Centhaquine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Centhaquine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pharmazz, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: PPharmazz, Inc.